Summary
This is a global, multicenter, open-label safety extension study. Participants receiving
single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination
with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are
active and receiving benefit at the closure of parent study are eligible for continued
treatment in this study.